Global Human Growth Hormone (HGH) 麻豆原创 Outlook 2022

You are here: 麻豆原创 Catalog Pharma & Healthcare Healthcare Country Overview (Pharma & Healthcare)

Global Human Growth Hormone (HGH) 麻豆原创 Outlook 2022

麻豆原创 Research Report Summary

Global Human Growth Hormone (HGH) 麻豆原创 Outlook 2022 report is published on March 2, 2017 and has 102 pages in it. This market research report provides information about Healthcare, Country Overview (Pharma & Healthcare), Pharma & Healthcare industry. It covers Global, North America, USA, Europe, Asia Pacific, Japan market data and forecasts. It is priced starting at USD 1,100.00 for Single User License (PDF) which allows one person to use this report.

Please read the description and table of contents of this research report given below to check whether it meets your research requirements. If not, then please do not hesitate to contact us using "Report Enquiry" form given below. We can customize this research report or suggest a new fully customized market research report to meet your research goals and data requirements.

Global Human Growth Hormone (HGH) 麻豆原创 Outlook 2022

Printer version

Send by email

Publication ID:听

ROC0317003

Publication Date:听

March 2, 2017

笔补驳别蝉:听

102

笔耻产濒颈蝉丑别谤:听

Rockville Research

颁辞耻苍迟谤颈别蝉:听

USD 1,100.00

Pay By Invoice

If you wish to purchase this report using bank/wire transfer against an invoice, please fill your details using request invoice form given below.

Globally Trusted Brand

We help executives from firms听to Start-ups听with their market research needs thus听we can help you too.听

Secure Checkout

You can shop confidently as your online payments are processed using PCI DSS compliant secure payment gateways on our website.

Frequently Asked Questions

If you have any pre-sales听questions related to this report please let us know using the "Report Enquiry" form below. This will help us provide you听with answers听so that you can purchase with confidence. If you wish to read about frequently asked questions by our customers please visit our .

Tabs

Description

HGH is a master hormone protein responsible for growth stimulation, development and regeneration of healthy cells. Deficiency of growth hormone leads to Growth Hormone Deficiency (GHD), which is a chronic disease affecting both children and adults. The report 鈥淕lobal Human Growth Hormone (HGH) 麻豆原创 Outlook 2022鈥� provides an in-depth analysis of global HGH market, focusing on Pediatric and Adult GHD.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level. The report has been segmented as following:-

麻豆原创 Segmentation
鈥� Paediatric GHD
鈥� Adult GHD
鈥� Other Disorders
麻豆原创 Segmentation by Geography
鈥� Europe
鈥� North America-The US
鈥� Asia Pacific-Japan
Key Vendors
鈥� Merck Serono
鈥� Novo Nordisk
鈥� Pfizer
鈥� Eli Lilly
鈥� F. Hoffmann-La Roche Ltd.

Table of Contents

1. Executive Summary
2. Research Methodology
3. Human Growth Hormone
3.1 Overview
3.2 The Pathophysiology of Growth Hormone
3.2.1 Molecular Basis of GH Action
3.2.2 Metabolic Effects of GH
3.3 Growth Hormone Deficiency
3.3.1 Pediatric GHD
3.3.2 Adult GHD
3.3.3 Other Diorders
3.4 Recombinant HGH
3.4.1 Inclusion Body Technology
3.4.2 Protein Secretion Technology
3.4.3 Mouse-Cell Technology
4. Human Growth Hormone 麻豆原创 Analysis
4.1 麻豆原创 Sizing
4.1.1 麻豆原创 Size by Value (Actual & Forecasted)
4.1.2 麻豆原创 Size by Volume (Actual & Forecasted)
4.1.3 麻豆原创 Share by Region
4.2 HGH 麻豆原创 by Segment
4.2.1 麻豆原创 Share
4.2.2 Pediatric GHD market
4.2.3 Adult GHD market
5. GH Deficiency Therapy
5.1 Diagnosis
5.2 Therapy for Various GHDs
5.3 Treatment Options
5.3.1 HGH Injections
5.3.2 HGH Releasers
5.3.3 麻豆原创opathic HGH
5.3.4 Others
5.4 Human Growth Hormone (HGH) Replacement
5.4.1 Overview
5.4.2 Benefits of HGH Replacement
6. Global HGH 麻豆原创 Regional/Country Analysis
6.1 Europe
6.1.1 Overview
6.1.2 rhGH 麻豆原创 Sizing (Actual & Forecasted)
6.1.1 Pediatric rhGH 麻豆原创 Sizing (Actual & Forecasted)
6.2 The US
6.2.1 Overview
6.2.2 rhGH 麻豆原创 Sizing (Actual & Forecasted)
6.2.1 Pediatric rhGH 麻豆原创 Sizing (Actual & Forecasted)
6.3 Japan
6.3.1 Overview
6.3.2 rhGH 麻豆原创 Sizing (Actual & Forecasted)
6.3.1 Pediatric rhGH 麻豆原创 Sizing (Actual & Forecasted)
7. Global HGH 麻豆原创 Dynamics
7.1 Industry Trends & Developments
7.1.1 Advent of Long-acting rhGH
7.1.2 Use of HGH as Performance Enhancers
7.1.3 Products Under Development
7.2 Growth Drivers
7.2.1 Prevalence of Pituitary Dysfunction
7.2.2 Low 麻豆原创 Penetration
7.2.3 Growing Geriatric Population
7.2.4 Rising Healthcare Expenditure and Affordability
7.3 Challenges
7.3.1 High Treatment Cost
7.3.2 Adverse Side-effects of rhGH
7.3.3 Illicit Uses of HGH
7.3.4 Reimbursement Issues for Patients
7.3.5 Poor Adherence to Therapy by Patient
7.3.6 Stringent Regulatory Approvals
8. Competitive Landscape
8.1 Brand Analysis
8.2 Drugs by Disorders
8.3 麻豆原创 Share by Competitors
9. Company Profiles
9.1 Merck Serono
9.2 Novo Nordisk
9.3 Pfizer
9.4 Eli Lilly
9.5 F. Hoffmann-La Roche Ltd.

List of Charts

Figure 1: Rockville Research 鈥� Research Methodology
Figure 2: Regulation of GH Secretion
Table 1: Regulation of the GH/IGF-I Axis
Figure 3. Multiple Sites of Growth Hormone Action
Table 2: Approved Doses for GHD by Nations
Figure 4: Global Human Growth Hormone (rhGH) 麻豆原创 Size by Value, 2012-16 (US$ Billions)
Figure 5: Global Human Growth Hormone (rhGH) 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 6: Global Human Growth Hormone (rhGH) 麻豆原创 Size by Volume, 2012-16 (US$ Billions)
Figure 7: Global Human Growth Hormone (rhGH) 麻豆原创 Size by Volume Forecasted, 2017E-22E (US$ Billions)
Figure 8: Global HGH 麻豆原创 Share by Region (2015)
Figure 9: Global HGH 麻豆原创 Share by Segment (2015)
Table 3: Benefits of GH Therapy for Established Indications
Figure 10. Diagnostic Approach to Short Stature Diagnosis Standard Therapies
Table 4: Various Tests for Diagnosis of Growth Hormone Deficiency
Figure 11: Europe rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 12: Europe rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 13: Europe Pediatric rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 14: Europe Pediatric rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 16: The US rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 17: The US rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 18: The US Pediatric rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 19: The US Pediatric rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Table 5: rhGH Current Dose & Regimen Approved in Japan
Figure 20: Japan rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 21: Japan rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 22: Japan Pediatric rhGH 麻豆原创 Size by V0alue, 2012-16E (US$ Billions)
Figure 23: Japan Pediatric rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 24: Somavartan rhGH Sequence
Table 6: Comparison of Somavartan with Daily rhGh
Table 7: Year 2 鈥� Somavartan Efficacy Comparison with daily rhGH
Table 8: Sports Enhancement Products
Figure 25: Prevalence of Anterior Pituitary Hormone Deficiencies
Figure 26: 麻豆原创 Penetration of rHGH Across Nations
Figure 27: Decline of HGH Levels with Age
Figure 28: Global Ageing Population, 2010-50
Figure 29: Global Healthcare Expenditure, 2005-16E (US$ Trillion)
Figure 30: Global Gross National Income, 2005-15 (US$ Billion)
Table 9: Prices for Popular Recombinant Human Growth Hormones
Table 10: Adverse Effects of GH Therapy
Figure 31: Poor Compliance with Daily rhGH Injections (Percent Skipping Injections)
Table 11: FDA-Approved Growth Hormone Deficiency Indications by Product
Table 12: Leading HGH Brands by Company
Table 13: List of Growth Hormones Generics by Indication & Dosage
Table 14: Drugs for Paeder Will Syndrome (PWS)
Table 15: Drugs for Turner鈥檚 Syndrome
Table 16: Drugs for Idiopathic Short Stature (ISS)
Table 17: Drugs for Small for Gestational Age (SGA)
Figure 32: Global rhGH 麻豆原创 Value Share by Competitors (2016)
Figure 33: Global rhGH 麻豆原创 Volume Share by Competitors (2016)
Figure 34: Merck Serono Revenue by Business Segment (FY2016)
Figure 35: Merck Serono Revenue by Business Segment (FY2016)
Figure 36: Novo Nordisk Human Growth Hormone Sales, FY2012-FY2016 (US$ Billion)
Table 18: Novo Nordisk 鈥� Growth Disorder R&D Pipeline
Table 19: Pfizer 鈥� Growth Hormone Deficiency Pipeline (as of 31st January, 2017)
Figure 37: Roche Revenue by Busisness Segment (FY2016)
Figure 38: Roche Ltd. Sales, FY2012-FY2016 (US$ Billions)

List of Tables
Table 1: Regulation of the GH/IGF-I Axis
Table 2: Approved Doses for GHD by Nations
Table 3: Benefits of GH Therapy for Established Indications
Table 4: Various Tests for Diagnosis of Growth Hormone Deficiency
Table 5: rhGH Current Dose & Regimen Approved in Japan
Table 6: Comparison of Somavartan with Daily rhGh
Table 7: Year 2 鈥� Somavartan Efficacy Comparison with daily rhGH
Table 8: Sports Enhancement Products
Table 9: Prices for Popular Recombinant Human Growth Hormones
Table 10: Adverse Effects of GH Therapy
Table 11: FDA-Approved Growth Hormone Deficiency Indications by Product
Table 12: Leading HGH Brands by Company
Table 13: List of Growth Hormones Generics by Indication & Dosage
Table 14: Drugs for Paeder Will Syndrome (PWS)
Table 15: Drugs for Turner鈥檚 Syndrome
Table 16: Drugs for Idiopathic Short Stature (ISS)
Table 17: Drugs for Small for Gestational Age (SGA)
Table 18: Novo Nordisk 鈥� Growth Disorder R&D Pipeline
Table 19: Pfizer 鈥� Growth Hormone Deficiency Pipeline (as of 31st January, 2017)

List of Figures
Figure 1: Rockville Research 鈥� Research Methodology
Figure 2: Regulation of GH Secretion
Figure 3. Multiple Sites of Growth Hormone Action
Figure 4: Global Human Growth Hormone (rhGH) 麻豆原创 Size by Value, 2012-16 (US$ Billions)
Figure 5: Global Human Growth Hormone (rhGH) 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 6: Global Human Growth Hormone (rhGH) 麻豆原创 Size by Volume, 2012-16 (US$ Billions)
Figure 7: Global Human Growth Hormone (rhGH) 麻豆原创 Size by Volume Forecasted, 2017E-22E (US$ Billions)
Figure 8: Global HGH 麻豆原创 Share by Region (2015)
Figure 9: Global HGH 麻豆原创 Share by Segment (2015)
Figure 10. Diagnostic Approach to Short Stature Diagnosis Standard Therapies
Figure 11: Europe rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 12: Europe rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 13: Europe Pediatric rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 14: Europe Pediatric rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 16: The US rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 17: The US rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 18: The US Pediatric rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 19: The US Pediatric rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 20: Japan rhGH 麻豆原创 Size by Value, 2012-16E (US$ Billions)
Figure 21: Japan rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 22: Japan Pediatric rhGH 麻豆原创 Size by V0alue, 2012-16E (US$ Billions)
Figure 23: Japan Pediatric rhGH 麻豆原创 Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 24: Somavartan rhGH Sequence
Figure 25: Prevalence of Anterior Pituitary Hormone Deficiencies
Figure 26: 麻豆原创 Penetration of rHGH Across Nations
Figure 27: Decline of HGH Levels with Age
m,Figure 28: Global Ageing Population, 2010-50
Figure 29: Global Healthcare Expenditure, 2005-16E (US$ Trillion)
Figure 30: Global Gross National Income, 2005-15 (US$ Billion)
Figure 31: Poor Compliance with Daily rhGH Injections (Percent Skipping Injections)
Figure 32: Global rhGH 麻豆原创 Value Share by Competitors (2016)
Figure 33: Global rhGH 麻豆原创 Volume Share by Competitors (2016)
Figure 34: Merck Serono Revenue by Business Segment (FY2016)
Figure 35: Merck Serono Revenue by Business Segment (FY2016)
Figure 36: Novo Nordisk Human Growth Hormone Sales, FY2012-FY2016 (US$ Billion)
Figure 37: Roche Revenue by Busisness Segment (FY2016)
Figure 38: Roche Ltd. Sales, FY2012-FY2016 (US$ Billions)

Companies Covered

Novo Nordisk, Pfizer, Eli Lilly and Company, Merck KGaA and F. Hoffmann-La Roche Ltd.

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Enquiry / Request Invoice

Report Inquiry

Do you have more questions related to this market research report after going through the description and table of contents?

We are here to help. Please use the form given below to let us know your questions related to this report.

Kindly use your official email address and contact number to ensure speedy response.

First Name *

Last Name *

Company *

Email Address *

Phone (Including International Code) *

Report Title *

Do you need invoice for purchasing this report? *

Address 1

Address 2

City/Town

Postal/Zip Code

Country

License Type

Your Inquiry *

CAPTCHA

This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Healthcare

Country Overview (Pharma & Healthcare)

Pharma & Healthcare

*Please note that the report cover image shown above is for representation purpose only. Actual report cover may vary.

听

Related 麻豆原创 Research Reports

Publication	Price
Global Amoxicillin Clavulanate Potassium API 麻豆原创 Growth 2025-2031 The global Amoxicillin Clavulanate Potassium API market size is predicted to grow from US$ 312 million in 2025 to US$ 438 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. Amoxicillin Clavulanate Potassium API is a compound antibiotic raw material consisting of amoxicillin and clavulanate potassium. It integrates amoxicillin's antibacterial activity with clavulanate potassium's 尾-lactamase inhibitory function to enhance antibacterial effects by inhibiting enzyme activity, used for treating sensitive bacterial infections in oral or injectable formulations. United States market for Amoxicillin Clavulanate Potassium API is estimated to increase from US$ million in 2024 to US$ million...Read more	USD 3,660.00
Global VC Powder 麻豆原创 Growth 2025-2031 The global VC Powder market size is predicted to grow from US$ 16.8 million in 2025 to US$ 20.7 million in 2031; it is expected to grow at a CAGR of 3.5% from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. A fine, white or off-white crystalline powder that is the pure form of vitamin C. It is water-soluble and used for its antioxidant properties. United States market for VC Powder is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for VC Powder is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for VC Powder is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR...Read more	USD 3,660.00
Global Peptide CRO Services 麻豆原创 Growth (Status and Outlook) 2025-2031 According to this study, the global Peptide CRO Services market size will reach US$ 900 million by 2031. Peptide CRO services refer to integrated outsourced R&D services provided by professional third-party R&D institutions around peptide drugs or functional peptide products, covering the entire process of peptide sequence design, solid phase synthesis, liquid phase purification, structure identification, modification (such as PEGylation, cyclization), impurity research, formulation development and CMC registration support. With the widespread application of peptide drugs in the fields of tumors, metabolic diseases, vaccine adjuvants, etc., customers' demand for process development and pilot-scale expansion of high-purity, long-acting, and difficult-to-synthesize peptides continues to grow, which has promoted the rapid development of the peptide CRO service market. This type of service has the characteristics of high professional barriers, strong entry barriers,...Read more	USD 3,660.00
Global Lyophilized Bead 麻豆原创 Growth (Status and Outlook) 2025-2031 According to this study, the global Lyophilized Bead market size will reach US$ 433 million by 2031. Lyophilized beads are miniaturized freeze-dried reagent cartridges created by dispensing precise volumes of liquid formulation into liquid nitrogen, followed by vacuum drying鈥攔esulting in uniform, spherical beads. Their well-defined size and high surface-area-to-volume ratio enable rapid dissolution and precise dosing, reducing pipetting errors and contamination risk. With moisture removed, these beads remain stable at ambient temperatures, eliminating the need for cold chain logistics. They are compatible with automated dispensing platforms and formats like plates, PCR tubes, and POCT cartridges, enhancing manufacturing throughput and simplifying user workflows. Currently, lyophilized bead technology is rapidly gaining traction in the in vitro diagnostics (IVD) industry, particularly in segments such as nucleic acid testing, immunoassays, and POCT. With advantages like...Read more	USD 3,660.00
Global Maropitant Citrate Injectable Solution 麻豆原创 Growth 2025-2031 The global Maropitant Citrate Injectable Solution market size is predicted to grow from US$ 267 million in 2025 to US$ 402 million in 2031; it is expected to grow at a CAGR of 7.1% from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. Maropitant Citrate Injectable Solution is a veterinary prescription medication commonly used in dogs and cats for the prevention and treatment of vomiting caused by various conditions, including motion sickness, gastroenteritis, and chemotherapy-induced nausea. Its active ingredient, maropitant, is a highly selective neurokinin-1 (NK1) receptor antagonist that works by inhibiting the action of substance P鈥攁 key neurotransmitter involved in the vomiting reflex鈥攂oth in the central and peripheral nervous systems. The injectable...Read more	USD 3,660.00

Clients Who Trust Us

Need tailor made market research solution? We can help you with that too.

Contact Us

About Us

At 麻豆原创 we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer鈥檚 needs, be it custom research or syndicated research reports.

Contact Us

麻豆原创 Research Reports, Inc
16192 Coastal Hwy
Lewes, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

Latest Blog Posts

Stay Connected

Disclaimer: 麻豆原创 has no affiliation to, and is not associated with any other website(s) or organization(s). We offer syndicated research reports (like country analysis, SWOT analysis, competitive intelligence, industry reports, company reports and market analysis & trends reports) and custom market research from our website 麻豆原创ResearchReports.com only.

If you are looking for a market research solution for your research requirements, please begin your search using the search box on top of this page or use our chat system to speak to our market research consultants or directly write to us.

麻豆原创